Takeda Pharmaceutical Company

Research Takeda Pharmaceutical Company (TAK) on Bullrun: market cap USD 58.00B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 58.00B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025JPY 4.46TJPY 112.93BJPY 746.07B65.3%n/aJPY 654.94BJPY 4.85TJPY 7.64T
FY2024JPY 4.58TJPY 208.07BJPY 746.69B65.5%231.38JPY 494.13BJPY 4.84TJPY 7.42T
FY2023JPY 4.17TJPY 178.22Bn/a67.5%n/aJPY 288.36BJPY 4.66TJPY 6.74T

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 58.00Bn/an/an/a
20252025-12-31USD 49.24B65.0n/an/a
20242024-12-31USD 41.98B30.8n/an/a
20232023-12-29USD 44.78B32.4n/an/a
20222022-12-30USD 48.50B29.4n/an/a
20212021-12-31USD 42.46B10.6n/an/a

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Takeda Pharmaceutical Company's market cap?

Takeda Pharmaceutical Company's market capitalization is USD 58.00B.

What does Takeda Pharmaceutical Company do?

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.